Monte Rosa Therapeutics (GLUE) Gets a Buy from Piper Sandler

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Monte Rosa Therapeutics (GLUE – Research Report), with a price target of $16.00. The company’s shares closed yesterday at $3.38.

According to TipRanks, Tenthoff is an analyst with an average return of -6.9% and a 34.07% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Legend Biotech, and Monte Rosa Therapeutics.

Currently, the analyst consensus on Monte Rosa Therapeutics is a Strong Buy with an average price target of $16.25, which is a 380.77% upside from current levels. In a report released yesterday, Wells Fargo also assigned a Buy rating to the stock with a $18.00 price target.

GLUE market cap is currently $225.6M and has a P/E ratio of -1.46.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Monte Rosa Therapeutics (GLUE) Company Description:

Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.

ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xopZ6vo2TAtbvCpKpopZ%2BjwaZ50aiqmmWknbKzrc%2BerK2hk6h6qLjUnmSgnaSoeqJ5wa6wZp6ipLpuvMipnKtlo5a7pbjEq2RqaGNognKBkWpq